PROCESS FOR PREPARING SPIROCYCLIC COMPOUNDS
20210087203 ยท 2021-03-25
Inventors
Cpc classification
International classification
Abstract
New spirocyclic ligands for use in metal catalysed asymmetric hydrogenation, hydroformylation, allylic substitution and a process for the production of the same from plant feedstocks.
Claims
1. A process for the production of of spirocyclic compounds, said process including the steps of; introducing or mixing at least one halogenated heterocyclic compound with iron or an iron containing complex; and introducing at least one organometallic compound.
2. A process according to claim 1 wherein the iron containing complex includes iron (III).
3. A process according to claim 1 wherein the iron or iron containing complex is in a catalytic amount.
4. A process according to claim 3 wherein the process includes substantially 5 mol. % of iron (III) catalyst.
5. A process according to claim 4 wherein the process ues any one or any combination of Fe(acac)3, FeCl3, Fe(dbm)3 and/or the like.
6. A process according to claim 1 wherein the organometallic compound is an aryl and/or alkyl magnesium halide (Grignard reagent).
7. A process according to claim 6 wherein the organometallic compound is an organozinc reagent.
8. A process according to claim 1 wherein the halogenated heterocycle is derived from plants or plant related compounds.
9. Iron(III)-catalyzed arylative spirocyclization of at least one halogenated heterocyclic compound.
10. A spirocyclic ligand suitable for use in metal catalysed asymmetric transformations wherein said ligand has the general formula ##STR00026##
11. A ligand according to claim 10 wherein Ar is an aromatic group.
12. A ligand according to claim 10 wherein L is a Lewis base ligating group.
13. A metal catalysed asymmetric hydrogenation, hydroformylation, allylic substitution using ligands with the general formula ##STR00027##
Description
[0006] It is therefore an aim of the present invention to provide a new method or process by which to synthesis heterocycles.
[0007] It is a further aim of the present invention to provide a new route to spirocyclic compounds.
[0008] It is a yet further aim of the present invention to address the abovementioned problems.
[0009] In a first aspect of the invention there is provided a process suitable for the production of spirocyclic compounds, said process including the steps of; [0010] introducing or mixing at least one halogenated heterocyclic compound with iron or an iron containing complex; and [0011] introducing at least one organometallic compound.
[0012] Preferably the iron containing complex includes iron (III), iron in the 3+ oxidation state. Typically the iron or iron containing complex is in a catalytic amount. Further typically the process includes substantially 5 mol. % of iron (III) catalyst.
[0013] We report here a new entry to spirocyclic heterocycles, in which inexpensive iron(III)-catalysts mediate an unprecedented and highly stereoselective arylative cyclization cascade reaction of modular, plant-derived precursors.
[0014] In one embodiment the process uses any one or any combination of Fe(acac).sub.3, FeCl.sub.3, Fe(dbm).sub.3 and/or the like.
[0015] Typically the organometallic compound is an aryl and/or alkyl magnesium halide (Grignard reagent).
[0016] Further typically the organometallic compound is an organozinc reagent.
[0017] In one embodiment the halogenated heterocycle is derived from plants or plant related compounds.
[0018] In a second aspect of the invention there is provided an iron(III)-catalyzed arylative spirocyclization.
[0019] Typically the spirocyclization is of at least one halogenated heterocyclic compound.
[0020] In a further aspect of the invention there is provided a spirocyclic ligand suitable for use in metal catalysed asymmetric transformations wherein said ligand has the general formula
##STR00001##
[0021] Typically Ar is an aromatic group. Further typically L is a Lewis base ligating group such as NR.sub.2, PR.sub.3 and/or the like.
[0022] Typically the ligands are for use in any one or any combination of metal catalysed asymmetric hydrogenation, hydroformylation, allylic substitution and/or the like.
[0023] We here report that the development of a 3-carbon novel and sustainable iron(III)-catalyzed arylative spirocyclization reaction (
Results and Discussion
[0024] Our strategy as outlined in
[0025] Landmark publications have identified key features of iron-mediated CC bond forming reactions; our strategic premise was that in the presence of suitable additives a low-valent iron species (formed in situ by reaction of readily available Fe(III) salts with Grignard reagents) would mediate the spirocyclization cascade process shown in
[0026] The tricyclic product 2a was delivered as a 6:1 ratio of diastereoisomers, in favour of the isomer in which the aryl rings are present in the trans-arrangement shown above (structural assignment based upon nOe experiments, Supplementary SX).
[0027] We built upon the encouraging initial results by next examining variation of solvent and the relative NMP content (Table 1); this screening process indicated that the optimum reaction medium was Et.sub.2O/NMP (1:1, Table 1 entry 10).
TABLE-US-00001 TABLE 1 Influence of solvent on iron-catalyzed cascade
[0028] The next phase of optimization examined a range of stable iron(III) catalysts in the arylative spirocyclization reaction (Table 2). It quickly transpired that the catalyst was essential for the reaction to take place (entry 1) and that iron(III) chloride was as effective a catalyst as Fe(acac).sub.3. When Grignard reagent was omitted, starting material was returned quantitatively.
[0029] At this stage of our studies we also noted that conversion and yields were consistently improved when an excess of Grignard reagents was employed, with 2.4 equivalents proving optimal. Iron complexes bearing bulkier ligands were less productive in the reaction (entries 7 and 8) but only Fe.sub.2(SO.sub.4).sub.3 (entry 9) proved ineffective, returning the starting material quantitatively.
TABLE-US-00002 TABLE 2 Influence of catalyst and Grignard stoichiometry 2.4 7 43 8 Fe(dpm).sub.3
2.4 39 100 9 Fe.sub.2(SO.sub.4).sub.3 2.4 0 0
dbm =
indicates data missing or illegible when filed
[0030] We turned to an examination of the scope of the reaction (Table 3). The arylative spirocyclization reaction is generally efficient with a range of commercially-sourced aryl Grignards. Only where chelating ortho-substituents are present (entry 13) was there a deleterious effect upon the yield (entry 13) In accord with 2a previous reports of the interaction of alkyl Grignard reagents with iron salts, the use of alkyl Grignard reagents in the spirocyclization reaction are not efficient, with only EtMgBr delivering products in detectable quantities (entry 14).
TABLE-US-00003 TABLE 3 Scope of Grignard component : 73 FeCl
: 72 6:1 2
:89 FeCl
:63 20:1 3
: 76 FeCl
: 34 trans-only 4
: 39 FeCl
: 52 13:1 5
: 96 FeCl
: 85 11:1 6
: 91 FeCl
: 41 trans-only 7
: 49 FeCl
: 0 8
: 88 FeCl
: 21 10:1 9
: 75 FeCl
: 42 trans-only 10
: 39 FeCl
: 55 11:1 11
: 74 FeCl
: 74 20:1 12
: 0 FeCl
: 0 13
: 88 FeCl
: 21 20:1 14
: 36 FeCl
: 0
indicates data missing or illegible when filed
[0031] The mechanisms in play during iron-catalyzed cross-coupling reactions are complex and often not well-understood, and this arylative cyclization may proceeds by one of several possible pathways. Thus, a low-valent pathway may be in operation, proceeding via an intermediate -aryl iron intermediate.sup.3 3 which cyclises to give an .sup.3-allyl iron species 4 (
[0032] Finally, the reaction may involve radicals, if the initial formed -FeC bond undergoes homolysis to give aryl radical 8, which cyclises to give 9; radical recombination will give the same .sup.1-intermediate 10 as postulated for the low-valent path.
[0033] In summary, we have designed and implemented a novel iron-catalyzed cyclization-anion capture process which delivers spiroheterocycles in good yield. The mechanistic features of these reactions are a focus of our research at this time and these data will be disclosed elsewhere, in due course.
[0034] Various potential halogenated heterocycles and precursors thereof are shown in Scheme 1.
[0035] Scheme 2 shows the potential non-aromatic template rings and Scheme 3 shows various points of possible attachment.
##STR00022##
##STR00023##
##STR00024##
[0036] Scheme 4 below shows a synthetic route to spirocyclic ligands for asymmetric transformations.
##STR00025##